---
title: "Cerebrolysin: The Neuropeptide Complex for Brain Recovery"
description: "A guide to Cerebrolysin - the porcine brain-derived neuropeptide complex used for stroke, TBI, and Alzheimer's recovery. Covers mechanism, research, dosing, side effects, and availability."
image: /images/articles/cerebrolysin.webp
published: 2026-02-14
category: peptide-guides
tags: ["cerebrolysin", "neuropeptides", "brain recovery", "nootropics", "neurotrophic"]
---

# Cerebrolysin: The Neuropeptide Complex for Brain Recovery

Cerebrolysin is one of those compounds that splits the medical world along geographic lines. In Russia, China, and much of Europe, it's a mainstream treatment for stroke and dementia.

In the United States, most neurologists have never heard of it.

This disconnect isn't because the research doesn't exist. There are over **200 clinical studies** on Cerebrolysin. It's because the regulatory and commercial environment makes it invisible to American medicine.

> **Key Takeaways**
>
> - Cerebrolysin is a porcine brain-derived peptide complex that mimics neurotrophic factors like BDNF and NGF
> - It's approved in **40+ countries** for stroke, TBI, and Alzheimer's, but not available in the US (no FDA submission)
> - Clinical trials show benefits for stroke recovery, traumatic brain injury, and cognitive function in dementia
> - Administration is injectable only (IM or IV), with typical nootropic protocols running 2-5 mL IM for 4-week cycles

## What Is Cerebrolysin?

Cerebrolysin is a peptide preparation derived from purified porcine (pig) brain tissue. It's manufactured by the Austrian pharmaceutical company **EVER Neuro Pharma** (formerly Ebewe Pharma) through a standardized enzymatic process that breaks down brain proteins into small peptides and free amino acids.

The final product contains roughly **25%** low-molecular-weight peptides (below 10 kDa) and **75%** free amino acids. It's the peptide fraction that provides the biological activity.

These peptides mimic the effects of naturally occurring neurotrophic factors, the proteins your brain uses to grow, maintain, and repair neurons. Think of it as a cocktail of brain-derived signaling molecules, not a single compound with a single target.

## How Cerebrolysin Works: Multiple Neuroprotective Pathways

Cerebrolysin works through multiple brain repair pathways simultaneously.

### Neurotrophic Factor-Like Activity

The peptides in Cerebrolysin produce effects similar to:

- **BDNF (brain-derived neurotrophic factor)** — supports neuron survival and growth
- **NGF (nerve growth factor)** — promotes neuronal maintenance
- **GDNF (glial cell line-derived neurotrophic factor)** — protects dopaminergic neurons

Research has shown that Cerebrolysin activates the same intracellular signaling cascades as endogenous neurotrophic factors, including the **PI3K/Akt** and **MAPK/ERK** pathways ([Hartbauer et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11358484/)).

### Neuroplasticity Enhancement

Cerebrolysin promotes synaptic remodeling and dendritic branching. In animal models, it increases the expression of **synaptophysin**, a marker of synaptic density ([Rockenstein et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16697710/)).

More synapses means more connections between neurons, which translates to better cognitive function and faster recovery from brain injuries.

### Anti-Apoptotic Effects

After a stroke or brain injury, many neurons die in the hours and days afterward through programmed cell death (apoptosis). Cerebrolysin inhibits this secondary cell death by modulating caspase activity and stabilizing mitochondrial function ([Onishchenko et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18180046/)).

### Anti-Inflammatory Properties

Neuroinflammation drives much of the damage in both acute brain injuries and chronic neurodegenerative diseases. Cerebrolysin reduces the activation of microglia (the brain's immune cells) and decreases production of pro-inflammatory cytokines like **TNF-alpha** and **IL-1 beta** ([Alvarez et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16439158/)).

### Amyloid Beta Reduction

In Alzheimer's research, Cerebrolysin has shown the ability to reduce amyloid beta deposition in animal models. It modulates the processing of amyloid precursor protein (APP) toward the non-amyloidogenic pathway ([Rockenstein et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16697710/)).

> **Key Finding:** Amyloid plaques are one of the hallmarks of Alzheimer's disease, and Cerebrolysin's ability to reduce them adds to its therapeutic potential.

## Clinical Evidence: What the Trials Show

### Stroke Recovery

This is where the evidence is strongest. The **CASTA study** (Cerebrolysin in Acute Stroke Treatment in Asia) evaluated Cerebrolysin in **1,070 acute stroke patients**. Subgroup analyses revealed significant benefits in patients with more severe strokes ([Heiss et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22627987/)).

A Cochrane review analyzing multiple stroke trials found improvements in global neurological status, though the authors called for more large-scale trials ([Ziganshina et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32573768/)).

The **E-COMPASS trial** (2017) combined Cerebrolysin with rehabilitation therapy and found significantly better motor recovery compared to rehabilitation alone. This suggests Cerebrolysin enhances the brain's ability to rewire during rehab.

### Traumatic Brain Injury

The **CAPTAIN trials** examined Cerebrolysin in moderate to severe TBI. Results showed improvements in cognitive recovery and neurological outcomes at 90 days post-injury ([Chen et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23390978/)).

TBI is notoriously difficult to treat. There are essentially no FDA-approved drugs for it. Even modest improvements are meaningful.

### Alzheimer's Disease

A study by Alvarez et al. (2006) found that **30 mL of Cerebrolysin daily for 4 weeks** produced cognitive improvements that persisted for up to 3 months after treatment ended ([Alvarez et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16439158/)).

The improvements were measured using the **ADAS-cog scale**, the standard instrument for Alzheimer's trials. Effect sizes were comparable to approved medications like donepezil.

### Cognitive Enhancement in Healthy Individuals

The evidence here is thinner but the interest is higher. There are limited controlled studies on Cerebrolysin in healthy people.

Anecdotal reports from the biohacking community describe improved focus, mental clarity, faster information processing, and better verbal fluency. The mechanisms are plausible: BDNF-like activity and increased synaptic density are the same processes targeted by exercise and other cognitive enhancers.

For more on neuropeptide compounds and their profiles, visit [PeptideArc.com](https://peptidearc.com).

## Administration

Cerebrolysin is available only as an injectable solution. It cannot be taken orally because the peptides would be destroyed by digestive enzymes.

- **Intramuscular (IM)** — for doses up to 5 mL; can be self-administered into the deltoid or gluteus
- **Intravenous (IV)** — for doses above 5 mL; diluted in normal saline and infused over 15-60 minutes; requires clinical supervision

Cerebrolysin should never be mixed with balanced amino acid solutions or given as a rapid IV push at high doses.

## Dosing Protocols

### Medical Protocols (From Clinical Trials)

| Condition | Dose | Route | Duration |
|---|---|---|---|
| **Acute stroke** | 30-50 mL daily | IV | 10-21 days (start within 24-72h) |
| **TBI** | 30 mL daily | IV | 5-10 days |
| **Alzheimer's/dementia** | 10-30 mL daily | IV | 4-week cycles, 2-4x/year |
| **Mild cognitive impairment** | 5-10 mL daily | IM or IV | 10-20 days |

### Biohacking/Nootropic Protocols

These are based on community experience rather than clinical trials:

- **Cognitive enhancement** — 2-5 mL IM, 3-5 times per week for 4-week cycles
- **Maintenance** — 2 mL IM, 2-3 times per week
- **Intensive protocol** — 5-10 mL daily (IM or slow IV) for 10-20 days, then break

Most people cycle Cerebrolysin rather than using it continuously. A common pattern is **20 days on, 2-3 months off**. The effects tend to persist beyond the treatment period because the structural changes (new synapses, improved neuronal health) don't disappear immediately.

### Starting Low

If you're new to Cerebrolysin, starting with **1-2 mL IM** is standard practice. Individual response varies considerably.

## Side Effects

Cerebrolysin has a strong safety profile based on decades of clinical use and multiple trials.

### Common (Mild)

- **Headache** — the most frequently reported, usually in the first few days
- **Dizziness or lightheadedness** — typically transient
- **Injection site pain** — standard for IM injections
- **Feeling of warmth or flushing** — during or shortly after injection
- **Nausea** — uncommon, especially at higher doses

### Uncommon

- **Agitation or irritability** — some users report feeling overstimulated at higher doses
- **Insomnia** — likely related to increased neural activity; avoid evening dosing
- **Appetite changes** — both increased and decreased appetite reported
- **Sweating** — occasionally reported during IV infusions

### Rare/Serious

- **Allergic reactions** — anyone with known allergies to porcine products should avoid Cerebrolysin entirely
- **Seizures** — reported in a very small number of epilepsy patients; generally contraindicated in active epilepsy

> **Key Finding:** A 2012 safety meta-analysis covering over 3,000 patients found that the overall adverse event rate with Cerebrolysin was similar to placebo ([Bornstein et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29484894/)).

## Where to Get Cerebrolysin: Availability and Legal Status

> **Important:** Cerebrolysin is approved in **40+ countries** but is NOT available in the US (no FDA submission has been made).

- **Where it's available** — registered and sold as a pharmaceutical product in over 40 countries, including Russia, China, South Korea, Austria, Germany, Mexico, and many others
- **Where it's not available** — not approved by the FDA, Health Canada, or the Australian TGA
- **How people get it** — typically sourced from international pharmacies, particularly from Eastern Europe or Mexico; import for personal use occupies a legal gray area
- **Quality concerns** — because Cerebrolysin is a branded pharmaceutical with a single manufacturer (EVER Neuro Pharma), counterfeiting is a concern; always verify packaging, batch numbers, and source authenticity

## Frequently Asked Questions

### Can Cerebrolysin regrow brain cells?

Cerebrolysin doesn't directly create new neurons in any proven way. What it does is support the survival of existing neurons, promote the growth of new connections (synaptogenesis), and protect damaged neurons from dying.

In animal models, it has shown some evidence of promoting neurogenesis in the hippocampus ([Tatebayashi et al., 2003](https://pubmed.ncbi.nlm.nih.gov/14643768/)), but this hasn't been confirmed in humans.

### How quickly does Cerebrolysin work?

Some users report noticeable cognitive effects within the first few days. In clinical trials for stroke, measurable neurological improvements appeared within 10-21 days.

For Alzheimer's patients, improvements on cognitive testing were seen after 4 weeks of treatment.

### Is Cerebrolysin safe for long-term use?

There's limited data on continuous long-term use because most clinical protocols are cyclical (treat for weeks, take months off). Decades of clinical use haven't raised major long-term safety flags, but formal long-term safety studies are lacking.

### Can I combine Cerebrolysin with other nootropics?

Common stacks include:

- **Cerebrolysin + [Semax](/articles/selank-semax-nootropic-peptides)** — another neurotrophic peptide
- **Cerebrolysin + P21** — a synthetic BDNF mimetic
- **Cerebrolysin + lion's mane mushroom** — a natural NGF stimulator

There are no formal interaction studies for these combinations. Start compounds one at a time so you can identify what's doing what.

### Does Cerebrolysin cross the blood-brain barrier?

Yes. The small peptide fragments (below 10 kDa) can cross the blood-brain barrier. This has been confirmed in animal pharmacokinetic studies.

### Is Cerebrolysin the same as cortexin?

No. Cortexin is a similar concept (brain-derived peptide preparation) but is manufactured by a different company using a different process. Both are used in Russian and Eastern European medicine for neurological conditions, but they're distinct products with separate clinical evidence.

### Can vegans or vegetarians use Cerebrolysin?

Cerebrolysin is derived from pig brain tissue, so it's an animal product. For those who avoid animal products, synthetic neurotrophic peptides like [Semax](/articles/selank-semax-nootropic-peptides) or P21 may be worth exploring as alternatives.

## The Bottom Line

Cerebrolysin sits in a fascinating position. It has more clinical evidence than most compounds in the nootropic and peptide space, yet it remains virtually unknown in American medicine.

The research on stroke recovery and Alzheimer's disease is genuinely compelling. The safety record over **40+ years** of widespread use is reassuring.

But it's not without limitations. The evidence includes many studies of moderate quality. It requires injection, which limits accessibility. And the lack of FDA approval means quality assurance depends entirely on sourcing from legitimate channels.

For people dealing with brain injuries, neurodegenerative conditions, or cognitive decline, Cerebrolysin represents an option backed by real science. For healthy individuals looking for cognitive enhancement, the rationale is plausible but less proven.

*This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any treatment protocol.*
